Supply Chain

Due to a higher than anticipated demand, Sanofi is carefully managing distribution of 50 mg doses of Beyfortus in the private market to fulfill existing orders and provide equitable access to remaining doses for the vaccine that protects infants against respiratory syncytial virus.

Mangal discusses the causes of the shortage and how pharma companies can find solutions.

Due to a global demand, treatments such as Adderall and Ritalin have been in short supply for the management of attention-deficit hyperactivity disorder.

Increase in new treatments also brings increase in logistical challenges for pharma.

As borders shut down during the pandemic, pharma learned some lessons about sourcing.

The 2013 Drug Supply Chain Security Act (DSCSA) established a framework for exchanging data when products are transacted throughout the US pharma supply chain. Its goal, by November 2023, is to enable unit-level traceability in a secure, interoperable manner. HDA’s Chip Davis talks about how pharma manufacturers must prepare for this implementation deadline.

Rafael Teixeira on building an end-to-end cold chain strategy to support global storage and distribution efforts.

Additional assistance necessary for patients prescribed specialty therapies.

The Biden administration has rolled out a broad initiative to promote domestic production of critical materials, including medicines and their ingredients.

Hannah Schofield and Lavan Thasarathakumar discuss what blockchain is, how it could help improve pharmaceutical supply chains, and the COVID-19 vaccine supply chain in particular, and touches on where we are already seeing blockchain technology being used in this area.

If telehealth is here to stay, how is the industry adjusting?

Mitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.

Ferdi Steinmann outlines a few supply chain lessons that all pharma companies can learn from the COVID-19 pandemic.

Taking stock of evolving practices in protecting the supply chain amid the pandemic, including partnering and planning for what’s next.

It is vital to begin asking questions about your company’s DSCSA readiness and compliance, as well as that of your strategic partners, writes Rob Besse.

MilliporeSigma's Robert McGuirk speaks with Pharma Exec about the role of supply chain robustness in helping to mitigate the risk of drug shortages

Coexisting with the DSCSA may hinder new legislative efforts.

How to navigate the production and reimbursement intricacies of bringing regenerative medicines from bench to bedside.

Tim Willis and Oliver Wack outline the role of alternative data in supply chain risk management, and the ancillary benefits that come from adopting such technology.

The next generation of supply chain shows an increasing need for blockchain technology.

How low-cost drugs can succeed in the specialty pharmacy channel.

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

Steve Cottrell assesses the risks of lapses in pharma's supply chain visibility and outlines what can be done to minimize them